Investors

Directorate Change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announces that at the AGM held earlier today, all resolutions were duly passed.

Further to the announcement of 28 June 2023, the Company confirms that Non-executive Directors Stephen Hammond and Chris Brinsmead have not put themselves for re-election as Directors and have therefore, with immediate effect, ceased to be Directors of the Company.

Neil Davidson, Chairman of OptiBiotix Health plc commented: "I would like to take this opportunity to offer our thanks to Chris Brinsmead and Stephen Hammond for their respective contributions and wise counsel during their time on the Board." 

The full voting results will be available on the website in due course here: https://www.optibiotix-ir.com/content/investors/

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.